Evidence map›Paper›PMID 39294162›Full record

ArticleScientific reports2024

Unveiling Lobophytum sp. the neuroprotective potential of Parkinson's disease through multifaceted mechanisms, supported by metabolomic analysis and network pharmacology.

Hussain T Bakhsh, Dalia H Abu-Baih, Rania H Abu-Baih, Entesar A Saber, Faisal H Altemani, Naseh A Algehainy, Mohammad A Alanazi, Fatma Alzahraa Mokhtar, Gerhard Bringmann, Usama Ramadan Abdelmohsen and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hussain T BakhshDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Dalia H Abu-BaihDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Deraya University, New Minia City, Minia, 61111, Egypt.
Rania H Abu-BaihDrug Information Center, Faculty of Pharmacy, Minia University, Minia, Egypt.
Entesar A SaberDepartment of Medical Science, Histology and Cell Biology, Faculty of Pharmacy, Deraya University, New Minia City, Minia, 61111, Egypt.
Faisal H AltemaniDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Naseh A AlgehainyDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Mohammad A AlanaziDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Fatma Alzahraa MokhtarFujairah Research Centre, Sakamkam Road, Fujairah, United Arab Emirates.
Gerhard BringmannInstitute of Organic Chemistry, University of Würzburg, Am Hubland, 97074, Würzburg, Germany. gerhard.bringman@uni-wuerzburg.de.
Usama Ramadan AbdelmohsenDeraya Center for Scientific Research, Deraya University, New Minia City, Minia, 61111, Egypt. usama.ramadan@mu.edu.eg.
Fatma Mohamed Abd El-MordyDepartment of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11754, Egypt. fatmamohammed.pharmg@azhar.edu.eg.ORCID 0000-0002-5554-2064

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A main feature of neurodegenerative diseases is the loss of neurons. One of the most prevalent neurodegenerative illnesses is Parkinson disease (PD). Although several medications are already approved to treat neurodegenerative disorders, most of them only address associated symptoms. The main aim of the current study was to examine the neuroprotective efficacy and underlying mechanism of Lobophytum sp. crude extract in a rotenone-induced rat model of neurodegeneration mimicking PD in humans. The influence of the treatment on antioxidant, inflammatory, and apoptotic markers was assessed in addition to the investigation of TH (tyrosine hydroxylase) immunochemistry, histopathological changes, and α-synuclein. Metabolomic profiling of Lobophytum sp. crude extract was done by using High-Resolution Liquid Chromatography coupled with Mass Spectrometry (HR-LC-ESI-MS), which revealed the presence of 20 compounds (1-20) belonging to several classes of secondary metabolites including diterpenoids, sesquiterpenoids, steroids, and steroid glycosides. From our experimental results, we report that Lobophytum sp. extract conferred neuroprotection against rotenone-induced PD by inhibiting ROS formation, apoptosis, and inflammatory mediators including IL-6, IL-1β, and TNF-α, NF-кB, and subsequent neurodegeneration as evidenced by decreased α-synuclein deposition and enhanced tyrosine hydroxylase immunoreactivity. Moreover, a computational network pharmacology study was performed for the dereplicated compounds from Lobophytum sp. using PubChem, SwissTarget Prediction, STRING, DisGeNET, and ShinyGO databases. Among the studied genes, CYP19A1 was the top gene related to Parkinson's disease. Dendrinolide compounds annotated a high number of parkinsonism genes. The vascular endothelial growth factor (VEGF) pathway was the top signaling pathway related to the studied genes. Therefore, we speculate that Lobophytum sp. extract, owing to its pleiotropic mechanisms, could be further developed as a possible therapeutic drug for treating Parkinson's disease.

Indexed as

MetabolomicsNetwork PharmacologyNeuroprotective AgentsParkinson DiseaseRotenonealpha-SynucleinAnimalsApoptosisDisease Models, AnimalMalePlant ExtractsRatsReactive Oxygen Speciesalpha-SynucleinNeuroprotective AgentsPlant ExtractsReactive Oxygen SpeciesRotenoneLobophytum sp.Network pharmacologyNeurodegenerative diseasesParkinson's diseaseRotenone (ROT)VEGF pathway

Identifiers

PMID39294162
PMCPMC11411073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.